Agency for Toxic Substances and Disease Registry: Draft toxicological profile for perfluoroalkyls. 2009, Atlanta, GA: Agency for Toxic Substances and Disease Registry
Lindstrom AB, Strynar MJ, Libelo EL: Polyfluorinated compounds: past, present, and future. Environ Sci Technol. 2011, 45: 7954-7961.
Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL: Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: data from the national health and nutrition examination survey (NHANES). Environ Sci Technol. 2007, 41: 2237-2242.
Kato K, Calafat AM, Wong LY, Wanigatunga AA, Caudill SP, Needham LL: Polyfluoroalkyl compounds in pooled sera from children participating in the National Health and Nutrition Examination Survey 2001–2002. Environ Sci Technol. 2009, 43: 2641-2647.
Needham LL, Grandjean P, Heinzow B, Jorgensen PJ, Nielsen F, Patterson DG, Sjodin A, Turner WE, Weihe P: Partition of environmental chemicals between maternal and fetal blood and tissues. Environ Sci Technol. 2011, 45: 1121-1126.
Liu J, Li J, Liu Y, Chan HM, Zhao Y, Cai Z, Wu Y: Comparison on gestation and lactation exposure of perfluorinated compounds for newborns. Environ Int. 2011, 37: 1206-1212.
Grandjean P, Andersen EW, Budtz-Jorgensen E, Nielsen F, Molbak K, Weihe P, Heilmann C: Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA. 2012, 307: 391-397.
Weihe P, Kato K, Calafat AM, Nielsen F, Wanigatunga AA, Needham LL, Grandjean P: Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. Environ Sci Technol. 2008, 42: 6291-6295.
Butenhoff JL, Gaylor DW, Moore JA, Olsen GW, Rodricks J, Mandel JH, Zobel LR: Characterization of risk for general population exposure to perfluorooctanoate. Regul Toxicol Pharmacol. 2004, 39: 363-380.
Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL: Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci. 2002, 68: 249-264.
Minnesota Department of Health: Groundwater health risk limits. 2007, St. Paul, MN: Minnesota Department of Health
Post GB, Cohn PD, Cooper KR: Perfluorooctanoic acid (PFOA), an emerging drinking water contaminant: a critical review of recent literature. Environ Res. 2012, 116: 93-117.
U.S. Environmental Protection Agency: Provisional health advisories for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). 2009, Washington, DC: U.S. Environmental Protection Agency
Minnesota Department of Health: Health Risk Limits for Perfluorochemicals. Report to the Minnesota Legislature. 2008, St. Paul, MN: Minnesota Department of Health
Post GB, Louis JB, Cooper KR, Boros-Russo BJ, Lippincott RL: Occurrence and potential significance of perfluorooctanoic acid (PFOA) detected in New Jersey public drinking water systems. Environ Sci Technol. 2009, 43: 4547-4554.
European Food Safety Authority: Opinion of the Scientific Panel on Contaminants in the Food chain on Perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts. The EFSA Journal. 2008, 653: 1-131.
White SS, Fenton SE, Hines EP: Endocrine disrupting properties of perfluorooctanoic acid. J Steroid Biochem Mol Biol. 2011, 127: 16-26.
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J: Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007, 99: 366-394.
DeWitt JC, Peden-Adams MM, Keller JM, Germolec DR: Immunotoxicity of perfluorinated compounds: recent developments. Toxicol Pathol. 2012, 40: 300-311.
Guruge KS, Hikono H, Shimada N, Murakami K, Hasegawa J, Yeung LW, Yamanaka N, Yamashita N: Effect of perfluorooctane sulfonate (PFOS) on influenza A virus-induced mortality in female B6C3F1 mice. J Toxicol Sci. 2009, 34: 687-691.
Peden-Adams MM, Keller JM, Eudaly JG, Berger J, Gilkeson GS, Keil DE: Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol Sci. 2008, 104: 144-154.
Minnesota Department of Health: Environmental Public Health Tracking & Biomonitoring. Report to the Minnesota Legislature. 2011, St. Paul, MN: Minnesota Department of Health
Barouki R, Gluckman PD, Grandjean P, Hanson M, Heindel JJ: Developmental origins of non-communicable disease: implications for research and public health. Environ Health. 2012, 11: 42-
Dietert RR: Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment. J Immunotoxicol. 2008, 5: 401-412.
van Loveren H, Germolec D, Koren HS, Luster MI, Nolan C, Repetto R, Smith E, Vos JG, Vogt RF: Report of the Bilthoven Symposium: Advancement of Epidemiological Studies in Assessing the Human Health Effects of Immunotoxic Agents in the Environment and the Workplace. Biomarkers. 1999, 4: 135-157.
Budtz-Jorgensen E, Keiding N, Grandjean P: Benchmark dose calculation from epidemiological data. Biometrics. 2001, 57: 698-706.
Hastie TJ, Tibshirani RJ: Generalized Additive Models (Monographs on Statistics and Applied Probability 43). 1990, Boca Raton, FL: Chapman and Hall/CRC Press
U.S. Environmental Protection Agency: Benchmark dose technical guidance. 2012, Washington, DC: Risk Assessment Forum, U.S. Environmental Protection Agency
EFSA Scientific Committee: Guidance of the Scientific Committee on Use of the benchmark dose approach in risk assessment. The EFSA Journal. 2009, 1150: 1-72.
Joas R, Casteleyn L, Biot P, Kolossa-Gehring M, Castano A, Angerer J, Schoeters G, Sepai O, Knudsen LE, Joas A: Harmonised human biomonitoring in Europe: activities towards an EU HBM framework. Int J Hyg Environ Health. 2012, 215: 172-175.
Fei C, McLaughlin JK, Lipworth L, Olsen J: Prenatal exposure to PFOA and PFOS and risk of hospitalization for infectious diseases in early childhood. Environ Res. 2010, 110: 773-777.
C8 Science Panel: Status Report: PFOA and immune biomarkers in adults exposed to PFOA in drinking water in the mid Ohio valley. March 16. C8 Science Panel (Tony Fletcher, Kyle Steenland, David Savitz). 2009, Available: http://www.c8sciencepanel.org/study_results.html [accessed March 26 2013]
DeWitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, Cunard R, Anderson SE, Meade BJ, Peden-Adams MM: Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol. 2009, 39: 76-94.
Corsini E, Avogadro A, Galbiati V, dell'Agli M, Marinovich M, Galli CL, Germolec DR: In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs). Toxicol Appl Pharmacol. 2011, 250: 108-116.
Corsini E, Sangiovanni E, Avogadro A, Galbiati V, Viviani B, Marinovich M, Galli CL, Dell'Agli M, Germolec DR: In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol Appl Pharmacol. 2012, 258: 248-255.
Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM: Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. J Occup Environ Med. 2006, 48: 759-770.